T0	Participants 58 77	malignant melanoma.
T1	Participants 189 208	malignant melanoma.
T2	Participants 411 443	patients with high-risk melanoma
T3	Participants 458 547	the patients had lesions greater than 1.70 mm thick and TNM stage IB or stage II disease.
T4	Participants 587 688	coumarin-treated group of 13 patients, and 10 recurrences in the placebo-treated group of 14 patients